# Non-intrusive Detection of Temporary Neurologic Impairment By Opioids

> **NCT04223609** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 14 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Oxycodone
- **DRUG:** Placebo
- **DEVICE:** EyeLink 1000 Plus
- **DIAGNOSTIC_TEST:** Oculo-Cognitive Addition test (OCAT)
- **DEVICE:** VT3mini - Eye Tracking Technology for OEMs

## Key facts

- **NCT ID:** NCT04223609
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-28
- **Primary completion:** 2022-04-11
- **Final completion:** 2022-04-11
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04223609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04223609, "Non-intrusive Detection of Temporary Neurologic Impairment By Opioids". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04223609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*